**Core Concept**
The HER2/neu receptor is a member of the epidermal growth factor receptor (EGFR) family and plays a crucial role in the pathogenesis of breast cancer. Overexpression of HER2/neu is associated with aggressive tumor behavior and poor prognosis in breast cancer patients.

**Why the Correct Answer is Right**
HER2/neu receptor is used as a target for therapy in breast cancer due to its overexpression in a subset of tumors. Trastuzumab, a monoclonal antibody, binds to the extracellular domain of HER2/neu, inhibiting its dimerization and subsequent activation of downstream signaling pathways. This leads to inhibition of tumor growth and delay in disease progression. The use of trastuzumab in combination with chemotherapy has become a standard treatment approach for HER2-positive breast cancer.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as HER2/neu receptor is not used for the treatment of osteosarcoma. HER2/neu overexpression is not a characteristic feature of osteosarcoma.
**Option B:** This option is incorrect as HER2/neu receptor is not used for the treatment of lung cancer. While HER2/neu overexpression can occur in some lung cancers, it is not a common feature of this disease.
**Option C:** This option is incorrect as HER2/neu receptor is not used for the treatment of colorectal cancer. HER2/neu overexpression is not a characteristic feature of colorectal cancer.

**Clinical Pearl / High-Yield Fact**
It is essential to identify HER2/neu status in breast cancer patients as it has significant implications for treatment and prognosis. HER2-positive breast cancer is associated with a poorer prognosis than HER2-negative breast cancer, and targeted therapy with trastuzumab can improve outcomes in these patients.

**Correct Answer:** D.